HC Wainwright & Co. Maintains Buy Rating for Spectrum Pharmaceuticals: Here's What You Need To Know

HC Wainwright & Co. Maintains Buy Rating for Spectrum Pharmaceuticals: Here's What You Need To Know

HC Wainwright & Co. has decided to maintain its Buy rating of Spectrum Pharmaceuticals SPPI and raise its price target from $10.00 to $12.00.

Shares of Spectrum Pharmaceuticals are trading up 5.79% over the last 24 hours, at $1.37 per share.

A move to $12.00 would account for a 775.91% increase from the current share price.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary strategy comprised of acquiring, developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it's current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor ("G-CSF") for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer ("NSCLC") tumors with various mutations.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Posted In: BZI-AAR-UPDATEAnalyst Ratings